This study enrolls people who will be having a salivary gland biopsy at ECMC. The purpose of the study is to learn more about the tissue that makes saliva (salivary gland tissue). Read More

Adults ages 18+.
People who need minor salivary gland biopsy for suspected Sjogren's Syndrome.

This study enrolls seniors ages 65+. The purpose of this study is to learn whether an in-home, remote art program will be enjoyable and engaging. Read More

Older adults, ages 65+.
Have internet access.

This study enrolls adults with pancreatic cancer. The purpose of this study is to learn whether an experimental device, a Tumor Treating Fields (TTFields) device called NovoTTF-100L(P), will be safe and effective when used with gemcitabine and nab-paclitaxel (chemotherapy medications typically used to treat this cancer). Tumor Treating Fields (TTFields) are low intensity electric fields delivered with a small medical device. The fields are used on top of area on your body where your cancer is. The purpose is to disrupt the activity of dividing cancer cells. Read More

Adults ages 18+.
Diagnosed with adenocarcinoma of the pancreas (pancreatic cancer).
Interested and assigned by the investigator to have therapy with gemcitabine and nab-paclitaxel.

This study enrolls infants who are very premature. The purpose of the study is to learn which medications can help very premature babies breathe more easily. Read More

Children (infants) who have just been born.
Infants born between 22 and 28 weeks gestation OR 401-1000 grams birth weight.
Infant's physician has decided to treat them with surfactant.

This study enrolls adults with aortic valve stenosis. The purpose of this study is to show whether using Sentinel, a medical device to collect debris, Read More

Adults ages 18+.
Diagnosed with severe aortic valve stenosis.
Scheduled to undergo a transcatheter aortic valve replacement (TAVR).

This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. Read More

Adults 18+
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.

This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer. Read More

Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.

This study enrolls adults who have been diagnosed with borderline personality disorder. This study is being done to see if the study drug called, BI 1358894, may help people with BPD in the future. Read More

Adults ages 18-65 years.
Diagnosed with Borderline Personality Disorder.

This study enrolls children and teens. The purpose of the study is to see which types of toothpaste give the most benefit to teeth. Read More

Children ages 10-14.
Presence of second molars or evidence of erupting permanent second molars.
Good general health

This study enrolls people with Multiple Sclerosis who have already enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC). The purpose of this study is to learn more about the experiences of people with MS who are having a natalizumab infusion. Read More

Adults ages 18+.
Have multiple sclerosis.
Are enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC),
Have taken natalizumab for the treatment of MS for at least six months.